Literature DB >> 25686651

Critical analysis of common canister programs: a review of cross-functional considerations and health system economics.

Trent Larson1, Ravindra Gudavalli, Dean Prater, Scott Sutton.   

Abstract

Respiratory inhalers constitute a large percentage of hospital pharmacy expenditures. Metered-dose inhaler (MDI) canisters usually contain enough medication to last 2 to 4 weeks, while the average hospital stay for acute hospitalizations of respiratory illnesses is only 4-5 days. Hospital pharmacies are often unable to operationalize relabeling of inhalers at discharge to meet regulatory requirements. This dilemma produces drug wastage. The common canister (CC) approach is a method some hospitals implemented in an effort to minimize the costs associated with this issue. The CC program uses a shared inhaler, an individual one-way valve holding chamber, and a cleaning protocol. This approach has been the subject of considerable controversy. Proponents of the CC approach reported considerable cost savings to their institutions. Opponents of the CC approach are not convinced the benefits outweigh even a minimal risk of cross-contamination since adherence to protocols for hand washing and disinfection of the MDI device cannot be guaranteed to be 100% (pathogens from contaminated devices can enter the respiratory tract through inhalation). Other cost containment strategies, such as unit dose nebulizers, may be useful to realize similar reductions in pharmacy drug costs while minimizing the risks of nosocomial infections and their associated medical costs. The CC strategy may be appropriate for some hospital pharmacies that face budget constraints, but a full evaluation of the risks, benefits, and potential costs should guide those who make hospital policy decisions.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Common canister; Healthcare-associated pneumonia; Metered-dose inhaler; Nosocomial infection; Nosocomial pneumonia

Mesh:

Year:  2015        PMID: 25686651     DOI: 10.1185/03007995.2015.1016604

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Estimated cost-savings from optimizing use of inhaled medications for inpatients with obstructive lung disease.

Authors:  Ryuhei Kondo; Jennifer Austin; Mary Akel; Vineet M Arora; Valerie G Press
Journal:  J Asthma       Date:  2022-03-10

2.  Hidden Costs of Multiple-Dose Products: Quantifying Ipratropium Inhaler Wastage in the Hospital Setting.

Authors:  Elissa S Y Aeng; Kaitlin C McDougal; Emily M Allegretto-Smith; Aaron M Tejani
Journal:  Can J Hosp Pharm       Date:  2021-04-01

3.  CD4(+)CD25(high)CD127(-) regulatory T-cells in COPD: smoke and drugs effect.

Authors:  Alessandra Chiappori; Chiara Folli; Francesco Balbi; Emanuela Caci; Anna Maria Riccio; Laura De Ferrari; Giovanni Melioli; Fulvio Braido; Giorgio Walter Canonica
Journal:  World Allergy Organ J       Date:  2016-02-12       Impact factor: 4.084

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.